Prescription Drug Monitoring Program Use: National Dental PBRN Results

被引:18
作者
McCauley, J. L. [1 ]
Gilbert, G. H. [2 ]
Cochran, D. L. [3 ]
Gordan, V. V. [4 ]
Leite, R. S. [5 ]
Fillingim, R. B. [4 ]
Brady, K. T. [1 ,6 ]
机构
[1] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA
[2] Univ Alabama Birmingham, Dept Clin & Community Sci, Birmingham, AL USA
[3] UT Hlth San Antonio, Dept Periodont, San Antonio, TX USA
[4] Univ Florida, Dept Restorat Dent Sci, Gainesville, FL USA
[5] Med Univ South Carolina, Dept Stomatol, Charleston, SC 29425 USA
[6] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA
关键词
behavior and behavior mechanisms; dentistry; substance-related disorders; substance abuse; prescription drug abuse; education; IMPLEMENTATION; DENTISTS; RESTORATIONS; CONCORDANCE; REDUCTIONS; PHYSICIANS; OPIOIDS; TRENDS; IMPACT; COMMON;
D O I
10.1177/2380084418808517
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Introduction: The American Dental Association recommends that dentists use a prescription drug monitoring program (PDMP) prior to prescribing an opioid for acute pain management. Objective: The objective of this study was to examine dentists' experiences using their state PDMP, as well as the impact that state-mandated registration policies, mandated use policies, and practice characteristics had on the frequency with which dentists used their PDMP. Methods: We conducted a web-based cross-sectional survey among practicing dentist members of the National Dental Practice-Based Research Network (n = 805). The survey assessed prescribing practices for pain management and implementation of risk mitigation strategies, including PDMP use. Survey data were linked with network Enrollment Questionnaire data to include practitioner demographics and practice characteristics. Results: Nearly half of respondents (n = 375, 46.6%) reported having never accessed a PDMP, with the most common reasons for nonaccess being lack of awareness (n = 214, 57.1%) and lack of knowledge regarding registration and use (n = 94, 25.1%). The majority of PDMP users reported the program to be very helpful (58.1%) or somewhat helpful (31.6%). Dentists reported that PDMP use most often did not change their intended prescribing behavior (40.2%), led them not to prescribe an opioid (33.5%), or led them to prescribe fewer opioid doses (25.5%). Presence of a mandated use policy was significantly associated with increased frequency of PDMP use across a variety of situations, including prior to 1) prescribing any opioid for pain management, 2) issuing refills, 3) prescribing to new patients, and 4) prescribing to patients deemed high risk. Conclusion: Findings suggest that the majority of dentists find PDMPs helpful in informing their opioid-prescribing practices. Whereas the existence of a state-mandated use policy is a consistent predictor of dentists' PDMP use, outreach and education efforts may overcome key barriers to use identified in this study.
引用
收藏
页码:178 / 186
页数:9
相关论文
共 39 条
  • [1] Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health
    Ali, Mir M.
    Dowd, William N.
    Classen, Timothy
    Mutter, Ryan
    Novak, Scott P.
    [J]. ADDICTIVE BEHAVIORS, 2017, 69 : 65 - 77
  • [2] American Dental Association, 2016, STAT US OP TREATM DE
  • [3] Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians
    Bao, Yuhua
    Pan, Yijun
    Taylor, Aryn
    Radakrishnan, Sharmini
    Luo, Feijun
    Pincus, Harold Alan
    Schackman, Bruce R.
    [J]. HEALTH AFFAIRS, 2016, 35 (06) : 1045 - 1051
  • [4] A survey of Physicians' Perspectives on the New York State Mandatory Prescription Monitoring Program (ISTOP)
    Blum, Cary J.
    Nelson, Lewis S.
    Hoffman, Robert S.
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2016, 70 : 35 - 43
  • [5] Prescription Drug Monitoring and Dispensing of Prescription Opioids
    Brady, Joanne E.
    Wunsch, Hannah
    DiMaggio, Charles
    Lang, Barbara H.
    Giglio, James
    Li, Guohua
    [J]. PUBLIC HEALTH REPORTS, 2014, 129 (02) : 139 - 147
  • [6] Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity
    Brown, Richard
    Riley, Moira R.
    Ulrich, Lydia
    Kraly, Ellen Percy
    Jenkins, Paul
    Krupa, Nicole L.
    Gadomski, Anne
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2017, 178 : 348 - 354
  • [7] Patterns of abuse and routes of administration for immediate-release hydrocodone combination products
    Cassidy, Theresa A.
    Oyedele, Natasha
    Mickle, Travis C.
    Guenther, Sven
    Budman, Simon H.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) : 1071 - 1082
  • [8] Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program
    Delcher, Chris
    Wagenaar, Alexander C.
    Goldberger, Bruce A.
    Cook, Robert L.
    Maldonado-Molina, Mildred M.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2015, 150 : 63 - 68
  • [9] Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers
    Deyo, Richard A.
    Hallvik, Sara E.
    Hildebran, Christi
    Marino, Miguel
    Springer, Rachel
    Irvine, Jessica M.
    O'Kane, Nicole
    Van Otterloo, Joshua
    Wright, Dagan A.
    Leichtling, Gillian
    Millet, Lisa M.
    Carson, Jody
    Wakeland, Wayne
    McCarty, Dennis
    [J]. JOURNAL OF PAIN, 2018, 19 (02) : 166 - 177
  • [10] Evaluating the impact of prescription drug monitoring program implementation: a scoping review
    Finley, Erin P.
    Garcia, Ashley
    Rosen, Kristen
    McGeary, Don
    Pugh, Mary Jo
    Potter, Jennifer Sharpe
    [J]. BMC HEALTH SERVICES RESEARCH, 2017, 17